New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome

spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) ( NDM-1)-producing spp. among late-onset VAP patients in different intensive care units (ICUs) of Meno...

Full description

Saved in:
Bibliographic Details
Published inInfection and drug resistance Vol. 12; pp. 373 - 384
Main Authors Elbrolosy, Asmaa M, Labeeb, Azza Z, Hassan, Dina M
Format Journal Article
LanguageEnglish
Published New Zealand Taylor & Francis Ltd 01.01.2019
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) ( NDM-1)-producing spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of NDM-1-producing infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. Sixty-four isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for NDM-1 MβL detection. isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of NDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. Out of 64 isolates, 42 (65.6%) proved to be NDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with NDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. A worldwide spread of spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of NDM-1-producing isolates among late-onset VAP patients.
AbstractList spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) ( NDM-1)-producing spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of NDM-1-producing infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. Sixty-four isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for NDM-1 MβL detection. isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of NDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. Out of 64 isolates, 42 (65.6%) proved to be NDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with NDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. A worldwide spread of spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of NDM-1-producing isolates among late-onset VAP patients.
Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). Purpose: The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. Materials and methods: Sixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. Results: Out of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. Conclusion: A worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients.
BACKGROUNDAcinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). PURPOSEThe aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients. MATERIALS AND METHODSSixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed. RESULTSOut of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients. CONCLUSIONA worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients.
Asmaa M Elbrolosy,1 Azza Z Labeeb,1 Dina M Hassan2 1Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt; 2Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP).Purpose: The aims of this study were to determine the prevalence of New Delhi metallo-β-lactamase (MβL) (blaNDM-1)-producing Acinetobacter spp. among late-onset VAP patients in different intensive care units (ICUs) of Menoufia and Kasr Al Ainy University Hospitals, to investigate the possible risk factors contributing to the acquisition of blaNDM-1-producing Acinetobacter infection, and to correlate between antimicrobial resistance pattern and therapeutic efficacy as well as clinical outcomes of these patients.Materials and methods: Sixty-four Acinetobacter isolates were collected from mechanically ventilated patients with suspected late-onset VAP and subjected to antimicrobial susceptibility testing. The modified Hodge test (MHT) and combined disk tests (CDT) were applied for blaNDM-1 MβL detection. Acinetobacter isolates with phenotypically confirmed MβLs production were subjected to a PCR assay to verify the presence of blaNDM-1 gene. The most obvious risk factors for acquisition of carbapenem resistance in VAP patients and treatment outcomes were also analyzed.Results: Out of 64 Acinetobacter isolates, 42 (65.6%) proved to be blaNDM-1 positive. The sensitivity and specificity of MHT were 52.38% and 41.67%, while for CDT they were 92.86% and 83.33%, respectively. Acinetobacter isolates showed high susceptibility to colistin (85.7%). The clinical response was better among VAP patients who received combined carbapenem plus colistin therapy than those who received colistin alone. Relapse of infection was detected in 12.5% (8/64) of VAP cases. The reported mortality reached 46.8% (30/64) of which 27 (64.3%) were infected with blaNDM-1-positive isolates. Prolonged duration of mechanical ventilation, longer hospital and ICU stays, and prior exposure to antibiotic therapy were by far the most important factors predisposing to carbapenem resistance among VAP patients.Conclusion: A worldwide spread of Acinetobacter spp. expressing carbapenemases represents a significant threat to the medical community. The current study addressed the high prevalence of blaNDM-1-producing Acinetobacter isolates among late-onset VAP patients. Keywords: Acinetobacter spp., blaNDM-1, late-onset ventilator-associated pneumonia
Author Hassan, Dina M
Elbrolosy, Asmaa M
Labeeb, Azza Z
AuthorAffiliation 2 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
1 Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com
AuthorAffiliation_xml – name: 2 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
– name: 1 Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com
Author_xml – sequence: 1
  givenname: Asmaa M
  surname: Elbrolosy
  fullname: Elbrolosy, Asmaa M
  email: asmaaelbrolosy@yahoo.com
  organization: Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com
– sequence: 2
  givenname: Azza Z
  surname: Labeeb
  fullname: Labeeb, Azza Z
  email: asmaaelbrolosy@yahoo.com
  organization: Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt, asmaaelbrolosy@yahoo.com
– sequence: 3
  givenname: Dina M
  surname: Hassan
  fullname: Hassan, Dina M
  organization: Department of Clinical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30809098$$D View this record in MEDLINE/PubMed
BookMark eNpdUstu1DAUjVARLaUr9sgSGySU4tiJ7bBAGrU8RqoA8dpad5ybmYwcO9gOiH_ga_gQvgkPM1QtXtjXPkfH18fnfnHkvMOieFjRc1bV8tny8sP5x0qJltV3ipOqkqoUreRHN-rj4izGLc2Dt6KW7F5xzKmiLW3VSfHzLX4nl2g3AxkxgbW-_P2rtGASjBCxnILvZjO4NVnkGZNfZQgDGaK3kDASGH0Gd3XpXcREvizekwnSgC7F52ScbRq6MK_LgHGICVzaoRu_RkfAdWTyPhA_J-NHfFDc7cFGPDusp8XnVy8_Xbwpr969Xl4srkpTyyaVIKVsDAqlJBNU9nUvkHeomEQqVWugE6JvFdSmF0pCg6KjkhnKkZteSsZPi-Vet_Ow1VMYRgg_tIdB_z3wYa0hpMFY1JXgILCFFYOmVm120Jh8Td71TVVXJmu92GtN82rEzuRnB7C3RG8jbtjotf-mBZeS1k0WeHIQCP7rjDHpcYgGrQWHfo6a5d8VrKlllamP_6Nu_RxctkozxpmssiU7wad7lgk-xoD9dTMV1bvQ6BwafQhNZj-62f81919E-B-hlsGj
CitedBy_id crossref_primary_10_3390_antibiotics8030148
crossref_primary_10_3390_antibiotics12010077
crossref_primary_10_52547_JoMMID_10_4_186
crossref_primary_10_3389_fmicb_2020_589253
crossref_primary_10_3390_antibiotics10111325
crossref_primary_10_22207_JPAM_18_1_59
crossref_primary_10_1371_journal_pone_0256308
crossref_primary_10_3389_fpubh_2022_870354
ContentType Journal Article
Copyright 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2019 Elbrolosy et al. This work is published and licensed by Dove Medical Press Limited 2019
Copyright_xml – notice: 2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2019 Elbrolosy et al. This work is published and licensed by Dove Medical Press Limited 2019
DBID NPM
AAYXX
CITATION
3V.
7XB
8C1
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.2147/IDR.S186924
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Public Health Database (Proquest)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Biological Sciences
ProQuest research library
ProQuest Biological Science Journals
Research Library (Corporate)
ProQuest - Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
Publicly Available Content Database
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
Medicine
EISSN 1178-6973
EndPage 384
ExternalDocumentID oai_doaj_org_article_163a6e9ab2a5489396cc7e02a5f5141c
10_2147_IDR_S186924
30809098
Genre Journal Article
GeographicLocations United States--US
Cairo Egypt
Egypt
GeographicLocations_xml – name: Cairo Egypt
– name: United States--US
– name: Egypt
GroupedDBID ---
0YH
29I
2WC
53G
5VS
8C1
8FE
8FH
8G5
ABUWG
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
C1A
CCPQU
DIK
DWQXO
E3Z
EBD
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
LK8
M2O
M48
M7P
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RPM
UKHRP
VDV
AAYXX
CITATION
3V.
7XB
8FK
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
TDBHL
5PM
ID FETCH-LOGICAL-c475t-a7775ce68872607f4f6e3de827e0789cad66f98a4cf687a5e6d072c03e3cf7723
IEDL.DBID RPM
ISSN 1178-6973
IngestDate Tue Oct 22 15:12:00 EDT 2024
Tue Sep 17 21:13:56 EDT 2024
Sat Aug 17 01:17:39 EDT 2024
Thu Oct 10 18:09:24 EDT 2024
Thu Sep 26 18:41:50 EDT 2024
Sat Sep 28 08:21:27 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords late-onset ventilator-associated pneumonia
blaNDM-1
Acinetobacter spp
Language English
License The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c475t-a7775ce68872607f4f6e3de827e0789cad66f98a4cf687a5e6d072c03e3cf7723
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9877-2433
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377045/
PMID 30809098
PQID 2232716885
PQPubID 3933157
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_163a6e9ab2a5489396cc7e02a5f5141c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6377045
proquest_miscellaneous_2186625471
proquest_journals_2232716885
crossref_primary_10_2147_IDR_S186924
pubmed_primary_30809098
PublicationCentury 2000
PublicationDate 2019-01-01
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-01
  day: 01
PublicationDecade 2010
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
– name: Macclesfield
PublicationTitle Infection and drug resistance
PublicationTitleAlternate Infect Drug Resist
PublicationYear 2019
Publisher Taylor & Francis Ltd
Dove Medical Press
Publisher_xml – name: Taylor & Francis Ltd
– name: Dove Medical Press
SSID ssj0000396472
Score 2.2151928
Snippet spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). The aims of this study were to determine the prevalence...
Background: Acinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). Purpose: The aims of this...
BACKGROUNDAcinetobacter spp. are increasingly important microbes involved in late-onset ventilator-associated pneumonia (VAP). PURPOSEThe aims of this study...
Asmaa M Elbrolosy,1 Azza Z Labeeb,1 Dina M Hassan2 1Department of Medical Microbiology and Immunology, Faculty of Medicine, Menoufia University, Shebin El-Kom,...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 373
SubjectTerms Acinetobacter
Acinetobacter spp
Antibiotics
Antimicrobial agents
Antimicrobial resistance
blaNDM-1
Colistin
Drug resistance
Genes
Intensive care
Intensive care units
Intubation
Laboratories
late-onset ventilator-associated pneumonia
Mechanical ventilation
Medical prognosis
Medicine
Metallo-β-lactamase
Methods
Mortality
Multidrug resistance
Multidrug resistant organisms
Nosocomial infections
Original Research
Patients
Pneumonia
Risk factors
Streptococcus infections
Ventilator-associated pneumonia
Ventilators
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQ_wQKMlLVU03T2PFPbwulKkigFbSot8hxxt2V2mS1mz30HXiaPgjPxEySbncREhduSeyDkxnPfBPPfMPYTqkAvbiJAjD2Esp4JVwFUVDVpPMZpCCpUPjLV31ypj6f5-drrb4oJ6ynB-4_3D7iBa_B-TLzORGlOB2CgRTvIvr6g9BZ39StBVOdDZZUYZn1nVWs0M7IvjiP2vLsfzr69u479WLK1IY76lj7_wY1_8yYXHNBxw_ZgwE78lG_5kfsHtSP2e64J5--3uOnd7VUiz2-y8d3tNTXT9hPtGf8CC4nU34FLZ23i1834tKH1l-hKxOzjvsVPRkf0WE7bXQicuZT1E4CpLzrS8TpWlAKdst_jMZ84GVdHPIuNbGaLy8ERvCESuuWRicNqij3dcVnTTPnzbJFHYen7Oz44-mHEzH0YhBBmbwV3hiTB9BokzACMlFFDbICm6EsjHXBV1pHZ70KUVvjc9BVarKQSpAhIoKXz9hW3dTwgnGvZUAz4mMk7qMylB50wHnWp9aUyids51Ykxayn3CgwVCHJFSi5YpBcwt6TuFZTiCe7e4DaUwzaU_xLexK2fSvsYti8iwIRU4ZhpLV5wt6uhnHb0VmKr6FZ4hwiCsTg2hwk7HmvG6uVSEThLnU2YWZDazaWujlSTycdtbeWxiDIfvk_3u0Vu4_ozvX_i7bZVjtfwmtEUG35ptssvwEgAxyn
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTttAEB61Qap6qVr6Z0qrrYQ4scX4Z9fuBYUCopVAEYWKm7Vej0kksEPiHHiHPk0fpM_EjL1JmqrqLc6urJVnZueb2Z1vALbyCMmL61IixV4y0iaSaYGl5KrJ1AToY8iFwqdn6uQy-nYVX7mE29Rdq5zvie1GXdSWc-S75MYCwvZJEu-P7yR3jeLTVddC4zGsBRQp-D1YOzg6G5wvsix-yJWWQVeYxy15dr8enn_6zn2YgmjFFbWM_f-CmX_flvzD_Rw_h2cON4p-J-gX8AirdXhy6k7G12F70HFQ3--Ii2VJ1XRHbIvBkp36_iX8pG1NHOLNcCRuseFjd_n7l7wxtjG35NHkuKWAJYcm-vxmtnfmcxYjUlLGpaJtTyT4t-Sb2I340R8IR886_SzaG4rFZHYtKZBncFo1PDqsSVOFqQoxruuJqGcNfXZ8BZfHRxdfTqRrySBtpONGGq11bJHEoCkQ0mVUKgwLTAKNzFtvTaFUmSYmsqVKtIlRFb4OrB9iaEsC8uFr6FV1hW9BGBVa2k1MWTIFUm5zg8rSvMT4ic4j48HWXDrZuGPeyChiYSFmJMTMCdGDA5bcYgrTZbd_1JPrzFlfRqDTKExNHpiY2XZSZS2tmJ5KAox71oPNudwzZ8PTbKlxHnxcDJP18ZGKqbCe0RzmC6QYW-958KZTk8VKQgLjqZ8mHugVBVpZ6upINRq2DN8q1Jqw9sb_l_UOnhJ8S7uE0Cb0mskM3xNEavIPzg4eAGjTFyQ
  priority: 102
  providerName: ProQuest
Title New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome
URI https://www.ncbi.nlm.nih.gov/pubmed/30809098
https://www.proquest.com/docview/2232716885
https://search.proquest.com/docview/2186625471
https://pubmed.ncbi.nlm.nih.gov/PMC6377045
https://doaj.org/article/163a6e9ab2a5489396cc7e02a5f5141c
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswEB3E6aWXonvVpgYLBDmFXrSQUm-OkzQtkEBIk8I3gaLI2IAtGbZ8yD_0a_oh_abOaHHioqdeDFukAQLzyHkjzrwBOEx9g15cWm4w9uK-VD6PMmM5VU1GyjUD41Gh8OWVuLj1v02CyR4EbS1MlbSv01kvny96-Wxa5VYuF7rf5on148ux8KREKtLvQAcB-ihEr45fj4or3boWj7rw9L-eXve-U-sll7rweMiRokEU7jiiSq__XyTz71zJR87n_Dk8a1gjG9WrewF7Jn8JR3EtO31_zG4eqqjWx-yIxQ-C1Pev4CeeZOzUzKcztjAl3bTz37_4XOlSLdCJ8WWl-oo-jI3omp22OEk4sxnikqgoqzoSMfrOKfm6ZD9GMWsUWdefWZWUmK02dxxjd-KjeUmj0wLByVSesWVRrFixKRHd5jXcnp_djC9404WBa18GJVdSykAbgacRxj7S-lYYLzOhKw1J1WuVCWGjUPnailCqwIhsIF098IynLXJ37w3s50Vu3gFTwtN4gChrSfUo1akyQuO8UA1CmfrKgcPWJMmyFttIMEghIyZoxKQxogMnZK7tFFLIrh4Uq7ukwUmCPFMJE6nUVQEJ7ERCa1wx_rLIEYfagYPW2EmzbdcJciUXA8gwDBz4tB3GDUe3KCo3xQbnkEQghtVy6MDbGhvblbTYckDuoGZnqbsjiPFK1LvB9Pv__ucHeIpkLqpfDx3AfrnamI9ImMq0C51wPOzCk5Ozq_i6W712wM8vE3xGW-cPoUwf0g
link.rule.ids 230,315,730,783,787,867,888,2109,12235,21400,27936,27937,33278,33279,33756,33757,43591,43817,53804,53806,74342,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgk4AXBONfYICRpj3NLMsfO-EFdWxTB2tVjQ7tLXKc81ppS0qbPuw78Gn4IHwm7hK3pQjx1tRWZOXufL87-37H2E4eAXpxZQVg7CUipSORFmAFVU2mOgAfQioU7vVl9yL6fBlfuoTbzF2rXOyJzUZdVIZy5PvoxgLE9kkSf5x8F9Q1ik5XXQuNu2yTqKow-No8PO4PzpdZFj-kSsugLcyjljz7p0fn779SH6YgWnNFDWP_v2Dm37cl_3A_J4_YQ4cbeacV9GN2B8otdq_nTsa32O6g5aC-3ePDVUnVbI_v8sGKnfr2CfuB2xo_guvRmN9ATcfu4tdPca1NrW_Qo4lJQwGLDo136M1k78TnzMeopIRLedOeiNNvQTexa_6tM-COnnX2gTc3FIvp_EpgIE_gtKxpdFShpnJdFnxSVVNezWv87PCUXZwcDz91hWvJIEyk4lpopVRsAMWgMBBSNrISwgKSQAHx1htdSGnTREfGykTpGGThq8D4IYTGIpAPn7GNsirhBeNahgZ3E20tUSDlJtcgDc5LtJ-oPNIe21lIJ5u0zBsZRiwkxAyFmDkheuyQJLecQnTZzR_V9Cpz1pch6NQSUp0HOia2nVQagyvGJ4uA8cB4bHsh98zZ8CxbaZzH3i2H0froSEWXUM1xDvEFYoytDjz2vFWT5UpCBOOpnyYeU2sKtLbU9ZFyPGoYvmWoFGLtl_9f1lt2vzvsnWVnp_0vr9gDhHJpmxzaZhv1dA6vES7V-RtnE78Bz9saHg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwED9BJ028IBh_FhhgpGlPM8vyx054QR1dtQGrqrGhvUWOY6-VtqS06cO-A5-GD8Jn4i5xW4oQb0lsRZbuzvc7--53ALt5ZNCLS8sNxl48kiriaWEsp6rJVAXGNyEVCp8NxMll9OkqvnL5TzOXVrnYE5uNuqg0nZEfoBsLENsnSXxgXVrEsNf_MPnOqYMU3bS6dhr3YUNGIvQ7sHF0PBieL09c_JCqLoO2SI_a8xyc9s7ffaWeTEG05pYa9v5_Qc6_Myf_cEX9R_DQYUjWbYX-GO6Zcgs2z9wt-RbsDVs-6rt9drEqr5rtsz02XDFV3z2BH7jFsZ65GY3ZranpCp7_-slvlK7VLXo3PmnoYNG5sS79mWyfuJ3ZGBWWMCprWhUxeuaUlV2zb90hc1Sts_esyVYspvNrjkE9AdWyptFRhVrLVFmwSVVNWTWvUQTmKVz2jy8-nnDXnoHrSMY1V1LKWBsUicSgSNrIChMWJgmkIQ57rQohbJqoSFuRSBUbUfgy0H5oQm0R1IfPoFNWpdkGpkSocWdR1hIdUq5zZYTGeYnyE5lHyoPdhXSyScvCkWH0QkLMUIiZE6IHRyS55RSizm4-VNPrzFlihgBUCZOqPFAxMe-kQmtcMb5ZBI-H2oOdhdwzZ8-zbKV9HrxdDqMl0vWKKk01xznEHYjxtjz04HmrJsuVhAjMUz9NPJBrCrS21PWRcjxq2L5FKCXi7hf_X9Yb2ERzyL6cDj6_hAeI6tL2nGgHOvV0bl4hcqrz184kfgOuDB5M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Delhi+metallo-%CE%B2-lactamase-producing+Acinetobacter+isolates+among+late-onset+VAP+patients%3A+multidrug-resistant+pathogen+and+poor+outcome&rft.jtitle=Infection+and+drug+resistance&rft.au=Elbrolosy%2C+Asmaa+M&rft.au=Labeeb%2C+Azza+Z&rft.au=Hassan%2C+Dina+M&rft.date=2019-01-01&rft.issn=1178-6973&rft.eissn=1178-6973&rft.volume=12&rft.spage=373&rft.epage=384&rft_id=info:doi/10.2147%2FIDR.S186924&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6973&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6973&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6973&client=summon